13-15th November 2017

Berlin, Germany

REGISTER BEFORE 25 AUGUST TO SAVE UP TO €800

Speakers

Expand/Collapse

Kristine Freude
Associate Professor, Group of Stem Cells & Embryology, Department
of Veterinary & Animal Sciences, University of Copenhagen

Kristine received her PhD at Max Planck Institute for Molecular Genetics and Free University, Berlin, Germany in Human Genetics in 2005. Afterwards she continued as a Postdoctoral fellow at UC Irvine, CA, USA, working on different aspects of developmental biology and stem cell research in the fields of diabetes and neuroscience. During her stay at UC Irvine, she was awarded with a 3-year postdoctoral fellowship from the California Institute of Regenerative Medicine (CIRM) to be trained as a stem cell scientist. Afterwards she moved to the University of Copenhagen, Denmark where she became Assistant Professor and is now an Associate Professor (2015-present) with a her main interest in neurodegeneration, stem cells models for diseases such as Alzheimer’s disease and frontotemporal dementia and gene editing with CRISPR-Cas9 to complete the disease model tool boxes.

Day One

Monday 13th November, 2017

13.40 | Modeling of Neurodegenerative Diseases in a Dish with the Help of CRISPR-Cas9

Conrad Lichtenstein
Chief Scientific Officer
Nemesis Bioscience

In 2014, Professor Conrad Lichtenstein, CSO, co-founded Nemesis Bioscience to use RNA-guided endonucleases for AMR inactivation. Previously, as CSO for Population Genetics Technologies, he developed bar-coding for simultaneous analysis of candidate genes in multiple genomes and the identification of rare variants in mixed DNA samples.   After a PhD at the MRC Laboratory of Molecular Biology in Cambridge, and a post-doctoral position at the University of Washington, Seattle, he held a faculty position at Imperial College London, and was then Professor of Molecular Biology at Queen Mary, University of London.   His research has included gene targeting by homologous recombination, RNAi engineering and transposition by DNA elements spreading antibiotic resistance in bacteria.

Day Two

Tuesday 14th November, 2017

11.40 | Antibiotic Resurrection Via Programmable RNA-guided Endonuclease Inactivation of Multiple Resistance Genes

Matteo Martufi
Senior Scientist
GSK

Day Two

Tuesday 14th November, 2017

09.40 | CRISPR as a Tool for Target Validation in Drug Discovery

Lin Wu
Director, Genome Modification Facility
Harvard University

Lin Wu received her Ph.D. from Columbia University in Molecular and Cellular Developmental Biology, and her Postdoctoral training from The Rockefeller University in Biomedical Genetics and Metabolic diseases. After working many years as an associate director at the Transgenic and Gene Targeting Facility of Massachusetts General Hospital, Harvard Medical School, Lin became the director of the Genome Modification Facility (GMF) at Harvard University in 2012. The GMF provides transgenic, gene targeting, and other services to investigators of Harvard University and its affiliated institutions, as well as to investigators within the US and abroad.  For more details, please see http://gmf.fas.harvard.edu/

Workshop A

Wednesday 15th November 2017

09.00 |
Optimising the Development and Application of CRISPR Derived Transgenic Mice Models

Day One

Monday 13th November, 2017

13.10 | CRISPR/Cas9 Genome Editing in Mice

Louise Baskin
Senior Product Manger
Dharmacon- a GE Healthcare Company

Louise Baskin is a Senior Product Manager at GE Healthcare with responsibility for Dharmacon synthetic RNA products. She joined Dharmacon RNA Technologies in 2005 and has since led the development and commercial launch of multiple genome-wide siRNA, microRNA, and CRISPR-Cas9 product lines, including specificity-enhanced siRNA, self-delivering siRNA, and the first genome-wide synthetic CRISPR RNA collection. She works closely with a respected team of R&D scientists to develop and expand Dharmacon tools and services for gene modulation. Louise studied biology at Creighton University and received her Master of Science degree in Molecular Biology and Genetics from Northwestern University.

Day One

Monday 13th November, 2017

11.40 | Hit Identification & Confirmation Strategies in Arrayed CRISPR-Cas9 Screening

Danilo Maddalo
Lab Head, Oncology Pharmacology
Novartis Institutes for BioMedical Research

Day Two

Tuesday 14th November, 2017

09.10 | Genome Editing Meets Mouse Modelling for Better Preclinical Tools

Viresh Patel
Global Marketing Director, Digital Biology Group
Bio-Rad Laboratories

Day One

Monday 13th November, 2017

09.40 | Sensitive Quantification of Genome Editing Events by Droplet Digital PCR

Mark Fife
Group Leader, Genetics & Genomics
The Pirbright Institute

Mark Fife is a complex-disease geneticist with extensive experience in complex trait analysis (QTL and association studies), candidate gene mapping and molecular genetics techniques in human and chickens. He has produced over 45 peer-reviewed publications and book chapters in this area before becoming Genetics and Genomics group leader. Mark’s skills and experience in analysis of complex genetic traits is highly applicable to the research conducted across The Pirbright Institute. His group’s research on genome-wide analysis of chicken host immunity has culminated in the identification and characterisation of important causal genes for important immune traits in chickens.  He is now conducting research involved in human and animal vaccine production.

Day Two

Tuesday 14th November, 2017

14.10 | Chicken IFITM Knockout Technology for Increased Vaccine Production

Dan Blat
Senior Scientist- Manager
Immunocore

A world leading biotech based in Oxford, UK, Immunocore’s proprietary TCR-based bi-specific biologic technology has shown promising results in early stage clinical trials. Dan Blat joined Immunocore in 2014 and he currently serves as a senior scientist-manager in the pre-clinical biology group, where he leads a team of scientists whose main activities include pre-clinical testing of drug candidates, assay development and more recently integrating the CRISPR technology into Immunocore’s drug screening and research platforms. Dan holds a PhD in Immunology from the Weizmann Institute of Science, where he developed CAR-redirected regulatory T cells as treatment for autoimmune diseases.

Day One

Monday 13th November, 2017

14.10 | Employing the CRISPR/Cas9 System in Pre-Clinical Testing of T cell Receptor-Based Bispecific Drug Candidates

Eric Paul Bennett
Associate Professor
University of Copenhagen

Eric P. Bennett’s 3 decades of research in the field of Glycobiology have been dedicated to understanding the biosynthetic events controlling human mucin-type O-glycosylation. These efforts have uncovered the human GalNAc-T gene family as the largest glycosyltransferase enzyme family covering a single known glycosidic. By use of the recently emerged nuclease targeting technologies, Eric for the last 7 years has focused on ways of establishing engineered isogenic cells lacking individual “glycogenes”1. During those efforts, Eric has established novel ways of enriching and determining the targeting efficiency2,3 of programmable nuclease targeting which has resulted in improved precise genome targeting workflows4

Day One

Monday 13th November, 2017

09.10 | Cellular Indel Profiles & Dynamics Induced by Different CRISPR/Cas9 Delivery Formats: Applying Ex Vivo Methodologies In Vivo

Rob Wolthuis
Head of the Oncogenetics Section, Department of Clinical Genetics
VU Medical Center

Rob Wolthuis holds a PhD on the regulation of signal transduction by Ras small GTPases. As a postdoctoral fellow, he studied the regulation of mitosis at the Gurdon Institute, University of Cambridge, UK. Back in the Netherlands, he worked as a junior group leader at the Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital in Amsterdam, focusing on cell cycle regulation by regulated protein destruction and cyclin-Cdk signaling. Currently, he leads the Oncogenetics laboratories at the Cancer Center Amsterdam. He is also a Cancer Biology theme leader in the VUmc/AMC alliance. The Oncogenetics labs are using functional genomics, cell biological assays and drug-response patterns to pinpoint the function of cancer-predisposing gene alterations and design novel cancer therapies.

Day Two

Tuesday 14th November, 2017

10.55 | Genome-Scale Synthetic Lethality Screens of Isogenic Cell Lines Reveal Targetable Cancer Vulnerabilities & Functional Gene Networks

Ryan Cawood
Chief Executive Officer
Oxford Genetics

Dr Ryan Cawood is CEO and Founder of Oxford Genetics Ltd and has been running the business for 6 years. He has a first class degree in Genetics, and a D. Phil. from Oxford University in the field of molecular virology and oncology. Ryan founded Oxford Genetics in 2011, a Synthetic Biology company developing scalable solutions for the biomanufacture of complex mammalian biologics. Under Ryan’s direction, the company has developed a range of molecular innovations that put it at the cutting edge for synthetic biology engineering and expression of recombinant proteins and viruses.

Day Two

Tuesday 14th November, 2017

10.10 | Developing Genome Wide CRISPR Libraries for Target Discovery

David Parry-Smith
Group Leader, Stem Cell Informatics
Wellcome Trust Sanger Institute

Dr Parry-Smith leads the Stem Cell Informatics Team. His role is to interact with scientists at all levels, understand and gather requirements for developing and maintaining informatics systems supporting Stem Cell Engineering. He is a biophysicist software developer interested in bioinformatics of genome editing using CRISPR/Cas9, algorithms for tracking lab processes and sequence pattern recognition.

Day One

Monday 13th November, 2017

11.10 | Learning From CRISPR/Cas9: Advancing Bioinformatics for Precision Gene Editing

Kevin Holden
Head of Synthetic Biology
Synthego

Kevin Holden is Head of Synthetic Biology at Synthego in Redwood City, California where he is responsible for integrating synthetic biology workflows, such as CRISPR genome engineering, into novel engineering and automation platforms.  He is also responsible for overseeing academic and industrial collaborations with key opinion leaders within the CRISPR community. He has over 10 years of biotechnology experience that includes synthetic biology, engineering metabolic pathways in microbes and collaborative research.  Kevin earned his PhD in Microbiology from University of California, Davis.

Day Two

Tuesday 14th November, 2017

11.25 | Synthetic sgRNA Enables Highly Efficient & Consistent CRISPR Editing of Primary Cells for Therapeutic Applications

Hao Yin
Scientist II
Vertex Pharmaceuticals

Workshop B

Wednesday 15th November 2017

12.00 |
Optimising In Vivo Delivery for Therapeutic Advancement of CRISPR Gene Editing

Day Two

Tuesday 14th November, 2017

13.40 | In Vivo Genome Editing: from Proof-of-Concept to Therapeutic Delivery

Pedro Costa
Sir Henry Wellcome Postdoctoral Fellow
King’s College London

Pedro is a Sir Henry Wellcome Postdoctoral fellow, having joined King’s College London in 2014. His research is focused on the synthesis/functionalisation of carbon-based nanocarriers for delivery of miRNAs and CRISPR/Cas9 to the brain. Pedro is also using CRISPR/Cas9 to investigate therapeutic synergies between oncogene knockout and chemotherapeutics in brain cancer stem cells. He has a Bachelor degree (B.Sc) in Biochemistry  and a Doctoral degree (Ph.D) in Biochemical Technology from the University of Coimbra (Portugal), during which he worked on the development of gene therapy strategies for treatment of malignant brain tumours, combining lipid-mediated miRNA silencing with tyrosine kinase inhibitors.